Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy
Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.
FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD
After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.
Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T
Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.
CGTLive®’s Weekly Rewind – July 19, 2024
Review top news and interview highlights from the week ending July 19, 2024.
Around the Helix: Cell and Gene Therapy Company Updates – July 17, 2024